MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two
stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and
tolerability of concurrent administration of MEK162 and RAF265, followed by an expansion part
to further assess the safety and preliminary anti-tumor efficacy of this oral combination
within two separate patient populations: i) patients with advanced solid tumors harboring
BRAFV600E mutations or ii) patients with advanced solid tumors harboring RAS mutations.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer